Prescription performance of the 3 major chronic disease treatments that Celltrion Pharm acquired from Takeda Pharmaceutical had fallen for 2 consecutive years since their acquisition.

The ‘Nesina’ series, which account for the most proportion of sales among the acquired products, recorded KRW 28.2 billion in sales last year, recording a downward trend for 3 consecutive years since 2020. Sales of the other diabetes treatment ‘Actos’ series and the hypertension treatment ‘Edarbi’ series have also shown sluggish sales in terms of prescription performance over the past 2 years.

According to the market research institution UBIST on the 8th, the total prescription amount of the 3 major chron